Table 5 Number of patients with deranged haematological results pre- and post treatment cycles

From: Peptide receptor radionuclide therapy with 90Y-DOTATATE/90Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity

  

Pre-treatment

Post treatment

 

Toxicity

Haematology

G1

G2

G1

G2

G3

G4

Total post treatment (%)

Cycle 1

Anaemia

24

0

37

4

0

0

41/57 (72)

(n=57)

Leucopoenia

1

0

14

8

6

0

28/57 (49)

 

Thrombocytopaenia

6

0

19

3

3

3

28/57 (49)

Cycle 2

Anaemia

23

1

27

3

4

0

34/48 (71)

(n=48)

Leucopoenia

7

0

11

7

7

0

25/48 (52)

 

Thrombocytopaenia

3

0

12

5

4

3

24/48 (50)

Cycle 3

Anaemia

16

4

25

5

1

0

31/36 (86)

(n=36)

Leucopoenia

6

2

17

6

4

0

27/36 (75)

 

Thrombocytopaenia

4

0

16

2

5

1

24/36 (66)

  1. Patients are categorised into grades 1–4 according to the severity of the toxicity as determined by the NCI CTCAE criteria.
Back to article page